1. Home
  2. CYTK vs HAE Comparison

CYTK vs HAE Comparison

Compare CYTK & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • HAE
  • Stock Information
  • Founded
  • CYTK 1997
  • HAE 1971
  • Country
  • CYTK United States
  • HAE United States
  • Employees
  • CYTK N/A
  • HAE N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • HAE Medical/Dental Instruments
  • Sector
  • CYTK Health Care
  • HAE Health Care
  • Exchange
  • CYTK Nasdaq
  • HAE Nasdaq
  • Market Cap
  • CYTK 6.7B
  • HAE 4.1B
  • IPO Year
  • CYTK 2004
  • HAE 1991
  • Fundamental
  • Price
  • CYTK $54.53
  • HAE $75.97
  • Analyst Decision
  • CYTK Buy
  • HAE Buy
  • Analyst Count
  • CYTK 15
  • HAE 7
  • Target Price
  • CYTK $83.93
  • HAE $106.14
  • AVG Volume (30 Days)
  • CYTK 1.1M
  • HAE 558.5K
  • Earning Date
  • CYTK 10-31-2024
  • HAE 11-07-2024
  • Dividend Yield
  • CYTK N/A
  • HAE N/A
  • EPS Growth
  • CYTK N/A
  • HAE N/A
  • EPS
  • CYTK N/A
  • HAE 2.23
  • Revenue
  • CYTK $3,134,000.00
  • HAE $1,333,895,000.00
  • Revenue This Year
  • CYTK N/A
  • HAE $7.79
  • Revenue Next Year
  • CYTK $827.22
  • HAE $5.32
  • P/E Ratio
  • CYTK N/A
  • HAE $34.02
  • Revenue Growth
  • CYTK N/A
  • HAE 9.47
  • 52 Week Low
  • CYTK $30.37
  • HAE $70.74
  • 52 Week High
  • CYTK $110.25
  • HAE $97.97
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 49.72
  • HAE 47.64
  • Support Level
  • CYTK $52.62
  • HAE $74.83
  • Resistance Level
  • CYTK $56.10
  • HAE $76.86
  • Average True Range (ATR)
  • CYTK 1.77
  • HAE 1.65
  • MACD
  • CYTK 0.17
  • HAE -0.16
  • Stochastic Oscillator
  • CYTK 54.36
  • HAE 29.58

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: